SGK1缺失通过促进对T细胞介导免疫的抵抗支持肝细胞癌转移定植
该研究在小鼠肝细胞癌转移模型中利用体内CRISPR文库筛选,发现Sgk1是T细胞免疫监视下转移定植的关键抑制因子。Sgk1缺失的肿瘤细胞在CD8+ T细胞存在时转移能力显著增强,机制上Sgk1失活减弱了CD8+ T细胞介导的RIPK1依赖性坏死性凋亡。肝细胞癌患者循环肿瘤细胞和转移灶中SGK1表达低于匹配原发灶,低表达与T细胞功能受损及较差临床结局相关。
要点
- Sgk1是T细胞免疫监视下肝细胞癌转移定植的关键抑制因子。
- Sgk1缺失的肿瘤细胞在CD8+ T细胞存在时转移能力显著增强。
- 肝细胞癌患者转移灶SGK1表达低于匹配原发灶,低表达与T细胞功能受损相关。
核心结论
- SGK1是肝细胞癌转移生长免疫控制的关键调节因子。
- 转移灶中SGK1表达可能作为免疫检查点抑制剂反应的预测生物标志物。
- Sgk1缺失通过消除CD8+ T细胞诱导的RIPK1依赖性坏死性凋亡赋予转移肿瘤细胞生存优势。
研究设计与样本
- 在小鼠肝细胞癌转移模型中,于T细胞免疫完整和T细胞免疫耗竭条件下进行体内CRISPR文库筛选。
- 采用多种实验方法研究Sgk1调控免疫逃逸的内在机制。
- 对肝细胞癌患者进行临床分析,比较循环肿瘤细胞、转移灶与匹配原发灶的SGK1表达。
主要发现
- 筛选鉴定Sgk1为T细胞免疫监视下转移定植的必需抑制因子。
- Sgk1缺陷肿瘤细胞在CD8+ T细胞存在时转移能力显著增强。
- 肝细胞癌患者循环肿瘤细胞和转移灶中SGK1表达显著低于匹配原发灶。
- 低SGK1表达与T细胞功能受损和较差临床结局相关。
- Sgk1失活减弱CD8+ T细胞介导的RIPK1依赖性坏死性凋亡,使肿瘤细胞逃避T细胞毒性。
临床怎么用
- 转移灶中SGK1表达可能作为预测免疫检查点抑制剂反应的生物标志物。
- 在转移定植早期给予免疫检查点抑制剂可逆转Sgk1沉默转移灶诱导的终末耗竭CD8+ T细胞浸润。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Immune evasion by tumor cells is a principal obstacle to effectively targeting metastasis in hepatocellular carcinoma (HCC). However, the specific molecular mechanisms facilitating immune escape during metastatic seeding are not fully elucidated. METHODS: Utilizing in vivo CRISPR library screening in murine HCC metastasis models under conditions of both intact and depleted T-cell immunity, we identified genes critical to tumor immune evasion during metastatic colonization and investigated intrinsic mechanisms using several experimental approaches. RESULTS: Our screens identified Sgk1 as an essential suppressor of metastatic colonization under T-cell immunosurveillance. Sgk1-deficient tumor cells displayed significantly enhanced metastatic capacity in the presence of CD8+ T cells, underscoring the role of Sgk1 in regulating immune escape. Clinical analyses corroborated these findings, showing markedly lower SGK1 expression in circulating tumor cells and metastatic lesions relative to matched primary tumors in patients with HCC, with low SGK1 expression associating with compromised T-cell function and poorer clinical outcomes. Mechanistically, Sgk1 inactivation in tumor cells attenuated CD8+ T cell-mediated, RIPK1-dependent necroptosis - a cell death pathway essential for cytotoxic T cell-mediated restriction of metastasis. Loss of Sgk1 consequently enabled tumor cells to circumvent T cell-induced cytotoxicity, thereby promoting metastatic colonization. Furthermore, the outgrowth of Sgk1-deficient metastatic cells induced a microenvironmental shift toward terminal T-cell exhaustion, establishing conditions conducive to sustained immune evasion. CONCLUSIONS: These findings establish SGK1 as a crucial regulator of immune-mediated control over metastatic growth in HCC. SGK1 expression in metastatic lesions may serve as a predictive biomarker for response to immune checkpoint inhibitors, presenting new avenues for therapeutic intervention to overcome immune resistance in metastatic HCC. IMPACT AND IMPLICATIONS: Despite metastasis being a common occurrence and lethal determinant in cancers, the mechanism underlying tumor immune evasion during metastatic seeding is unclear. Our study reveals that loss of Sgk1 confers metastatic tumor cells with a survival advantage by abrogating CD8+ T cell-induced RIPK1-dependent necroptosis. Growth of Sgk1-silenced metastasis led to infiltration of terminally exhausted CD8+ T cells, which could be reversed by immune checkpoint inhibitors administered at an early stage of metastatic seeding. These findings provide valuable insights into potential therapeutic strategies targeting resistance to T-cell immunity in cancer metastasis.
引用
- Zhang Z, Geng C, Song M, et al. Loss of SGK1 supports metastatic colonization in hepatocellular carcinoma by promoting resistance to T cell-mediated immunity. J Hepatol. 2025. PMID: 39892819. doi:10.1016/j.jhep.2025.01.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。